Core Insights - The company Xtep has achieved significant success at the recently concluded 15th National Games, with athletes wearing Xtep apparel winning a total of 18 medals, including 9 gold medals [2] - Xtep has established a strong presence in the running sector through systematic research and innovation, developing four major technology platforms: XTEP FIT, XTEP DURA, XTEP ACE+, and XTEP POWER, which cater to various technical needs of athletes [2] - The XTEP FIT technology is based on data from 300,000 foot shapes of Chinese individuals, ensuring a stable fit during long-duration high-intensity competitions [2] - Xtep has built a technical barrier in the professional endurance sector, having assisted 107 domestic athletes in winning a total of 507 marathon championships as of August this year [3] - In the marathon sector, Xtep achieved the highest overall wearing rate in six core events by 2025, with the Beijing Marathon leading at a 32.8% wearing rate for three consecutive years [3]

针对冰雪出游需求，神州租车今年在延庆区域升级车队矩阵，新增投放坦克300、问界M7/M9等高通过 性、强智能配置的SUV车型，配合区域内超千台SUV车队的规模优势，为家庭游、年轻群体等不同客群 提供多样化选择。 延庆是京西北生态旅游重镇，冬季冰雪资源突出。自1984年首届冰雪节至今，延庆冰雪欢乐季已发展为 集滑雪、冰玩、民俗、研学于一体的综合性冰雪品牌，年接待游客约400万人次。此次神州租车推出的 一站式出行解决方案，精准匹配游客冬季冰雪出行需求，让"玩转延庆"变得更简单。游客通过神州租车 APP预订"京津冀优选"车辆，支持异地取还车直达雪场。此外，"租+滑"冰雪大礼包还将叠加雪票折 扣、景区优惠等权益，将租车服务与冰雪体验深度绑定。 中证报中证网讯（记者 王辉）11月22日，北京市延庆区第四十届冰雪欢乐季正式启动。作为本届活动 的企业合作伙伴，神州租车携"租+滑"冰雪大礼包亮相，通过整合租车服务与冰雪旅游资源，在本届冰 雪欢乐季为游客提供从城区到雪场的一站式出行解决方案，也为延庆冰雪季注入了便捷化、品质化的出 行选择。 ...

泰恩康介绍，CKBA来自乳香天然产物，是一种新型免疫调节剂，与传统免疫抑制剂相比更具靶向性和 安全性，非常适合儿童白癜风用药以及后续的维持治疗。基于CKBA治疗白癜风独特的靶点和机制， CKBA乳膏有望获批首个2-12岁儿童白癜风创新药，并成为白癜风维持治疗的首选药物。经测算，仅考 虑儿童白癜风用药，CKBA获批后国内年度销售峰值有望超50亿元。 11月20日，泰恩康公告，控股子公司博创园的CKBA乳膏(化学药品1类)申报2-12岁儿童白癜风II期临床 试验获国家药监局受理。 中证报中证网讯(王珞)泰恩康（301263）11月21日披露投资者活动关系记录表。公司在回答投资者提问 时表示，目前全球范围内2-12岁儿童白癜风尚无获批药物，现有疗法多为超说明书使用；国内白癜风患 者人数预测超3000万，儿童白癜风患者约占总白癜风患者的32%-40%，儿童白癜风存在巨大未被满足的 临床需求，按年治疗费用1.5万元-2万元简单测算，儿童白癜风市场规模超千亿元。 ...

Core Insights - Yuanrong Qixing showcased multiple models equipped with its combined auxiliary driving solutions at the 2025 Guangzhou Auto Show, demonstrating the adaptability and scalability of its systems across various vehicle types including SUVs, MPVs, and off-road vehicles [1] - As of now, Yuanrong Qixing has delivered 200,000 mass-produced vehicles equipped with its City NOA (Navigation Auxiliary Driving) system, with a target to exceed 1 million cumulative deliveries by 2026 [1] - The company achieved nearly 40% market share in the third-party City NOA market within just over a year, reflecting strong recognition of its technological capabilities and delivery performance [1] Business Development - Yuanrong Qixing's auxiliary driving solutions have contributed to the sustained sales growth of its partner models, while the company accelerates its Robotaxi business [2] - A strategic agreement was reached with the Wuxi municipal government to establish a testing and R&D base, with plans to launch Robotaxi services using consumer-grade mass-produced vehicles by the end of this year [2] - Unlike the traditional "modified vehicle + high-precision map" approach, Yuanrong Qixing's Robotaxi vehicles are built on consumer-grade mass-produced cars, resulting in lower deployment costs and enhanced system stability and platform compatibility [2] Technological Advancements - Yuanrong Qixing is advancing its RoadAGI initiative through its self-developed VLA model, which integrates VLA and VLN core models to enable mobile intelligent agents to navigate autonomously in real environments using natural language commands [2] - The application scenarios for RoadAGI include public roads, campus pathways, and indoor shopping malls, facilitating "any point to point" navigation [2]

中证报中证网讯(记者傅苏颖)日前，在德国杜塞尔多夫国际医院及医疗设备展览会(MEDICA2025)上， 怀柔科学城首次参展，累计接待超过1500家机构咨询，德国西门子医疗、瑞士联邦出口与投资促进机 构、德中经济联合会、西班牙卡斯蒂利亚-莱昂自治区政府等30余家机构与企业代表明确表达了近期赴 怀柔科学城实地考察的意向，并期待进一步合作。 怀柔科学城展区分为概况、科研成果展示与国际交流三部分，全景展示了其围绕物质、空间、生命、地 球系统、信息与智能五大科学方向布局的37个科学设施平台，重点展示了医疗影像等生命科学领域的大 科学设施平台与前沿成果，生动呈现"聚人气、聚科研气"的良好态势。 同时，西班牙外贸与投资促进局、德国联邦经济与气候保护部、瑞士出口与投资促进机构、慕尼黑工业 大学等机构主动到访怀柔科学城展位，详细了解科学城建设进展后，对大科学装置集群的开放共享机制 和科研生态氛围给予了高度评价。高校院所等机构代表进一步表达了在人才交流与联合研究等方面的合 作意愿。部分国内生命健康领域参展企业也来到展位，探讨入驻落地及技术合作的可能性。 据悉，怀柔科学城已进入运行为主的新阶段，4个大科学装置通过国家验收并运行，1 ...

Core Viewpoint - The company, Nanxin Pharmaceutical, is leveraging its technological advantages in the field of cold and antiviral drugs to ensure the production and supply of related treatment medications amid rising influenza virus activity levels in China [1][2]. Group 1: Product Portfolio and Innovation - Nanxin Pharmaceutical has established a comprehensive product matrix for influenza prevention and treatment, covering injectable and oral forms, as well as therapies for viral and bacterial infections, and antipyretic analgesics [1]. - The company's Palivizumab Sodium Injection is a representative of neuraminidase inhibitors, recognized as a core choice for influenza treatment in the latest national guidelines [1]. - The company is currently in the III phase of clinical trials for an inhalation solution of Palivizumab, which utilizes nebulization for direct action on the respiratory tract, enhancing patient compliance and offering a new option for influenza treatment [2]. Group 2: Targeted Treatments for Specific Populations - The company has developed a formulation of Oseltamivir Phosphate suitable for young children and elderly patients, addressing the need for appropriate dosage forms in these demographics [1]. - Nanxin Pharmaceutical offers a range of supportive treatments for influenza symptoms, including exclusive products like Compound Ibuprofen Tablets and formulations specifically designed for children, which have become common choices in pediatric care [2]. Group 3: Future Outlook and Commitment - The company aims to continuously optimize its product structure and provide efficient solutions for the prevention and treatment of influenza and other respiratory diseases, demonstrating its commitment to public health [2].

Core Insights - The exhibition "Outstanding · Within Reach" was held in Shanghai from November 21 to 23, showcasing immersive interactive display technologies to the public for free [1][2] - The theme "Display · Interaction · Perception of the Future" aimed to bring cutting-edge display technology to the streets, allowing the public to experience technological transformations firsthand [1] Industry Highlights - Leading companies in the display industry showcased their latest products and technologies, including BOE's AI smart display and AR/VR devices for home and office applications [2] - Visionox demonstrated the flexibility and innovative forms of display screens through flexible screen interactions [2] - Tianma Microelectronics and AUO presented a "Future Mobility Experience Cabin" featuring a multi-screen interactive infotainment system for future vehicles [2] - Hisense showcased an RGB MiniLED living room system that replicates a cinema-level audio-visual experience [2] - Yunshi Technology's electronic fish tank created a tranquil healing space amidst the bustling city with realistic imagery [2] Organizational Background - The Society for Information Display (SID) was established in 1962 and is headquartered in Silicon Valley, USA, recognized as a globally influential professional organization in the display field [2] - The exhibition effectively promoted the popularization of display technology and industry integration through scenario-based and interactive presentations, reflecting China's active exploration and market vitality in new display applications [2]

Group 1 - 16 hard technology-themed funds have been approved, including 7 AI ETFs, 3 chip ETFs, 4 chip design ETFs, and 2 actively managed technology equity funds from various fund managers such as E Fund, GF Fund, and Invesco Great Wall Fund, expected to be launched soon [1] - QDII products, represented by indices like Nasdaq 100 and S&P 500, have tightened subscription limits, with some products suspending subscriptions due to high premium rates in the market, indicating a disparity in technology asset performance across different markets [1] - MSCI announced the results of its index review for November 2025, which will take effect after the market closes on November 24, including the addition of 26 Chinese stocks and the removal of 20 stocks from the MSCI China Index [1]

Core Viewpoint - Guozi Software has demonstrated steady growth in its performance, with a solid foundation for annual growth due to sufficient orders and favorable industry policies [1][2]. Financial Performance - From 2022 to 2024, Guozi Software's revenue increased from 200 million to 268 million, maintaining a double-digit compound annual growth rate [1]. - Net profit rose from 51.85 million to 61.45 million, indicating a steady improvement in profitability [1]. - In the first three quarters of 2025, the company achieved revenue of 171 million, a year-on-year increase of 18.31%, and net profit of 33.70 million, up 27.46%, with net profit growth outpacing revenue growth [1]. Industry Outlook - The management holds an optimistic view on the industry, noting that China's software and information technology service sector is in a high-growth phase without significant cyclical characteristics [2]. - Continuous government policies are promoting digitalization in administrative and educational sectors, providing a favorable environment for industry growth [2]. - Guozi Software serves a wide range of clients across various administrative levels and sectors, which supports stable revenue growth [2]. Business Strategy - The company is expanding its industrial business through the acquisition of specifications intelligence, enhancing its growth potential [2]. - Guozi Software emphasizes compliance with regulations and transparent information disclosure, ensuring long-term strategic decision-making [2]. Investor Relations - The company encourages investor engagement through various communication channels to ensure transparency and participation [3]. - Future plans include consolidating core business advantages while seizing opportunities in digital transformation, focusing on technological innovation and market expansion [3].

Core Viewpoint - Aerospace Electric plans to acquire 32% equity in Shenzhen Aerospace Electric Motor System Co., Ltd. for a base price of 46.59 million yuan, aiming to increase its ownership from 68% to 100% and make it a wholly-owned subsidiary [1] Group 1: Acquisition Details - The acquisition will be conducted through a public listing, with the goal of accelerating the company's civil motor industry layout and integrating motor business [1] - Aerospace Electric currently holds 68% of Aerospace Electric Motor System, which was established in April 2015 with a registered capital of 50 million yuan [1] - The financial performance of Aerospace Electric Motor System includes revenue of 36.16 million yuan and net profit of 2.30 million yuan for the first half of 2025, and revenue of 72.79 million yuan with a net profit of 6.94 million yuan for 2024 [1] Group 2: Company Performance - Aerospace Electric's main business includes high-end connectors, micro motors, relays, and optoelectronic devices, along with providing integrated solutions [2] - In the first three quarters of the year, the company achieved revenue of 4.349 billion yuan and a net profit of 131 million yuan [2] - In the third quarter, the company reported revenue of 1.414 billion yuan, a year-on-year increase of 31.73%, and a net profit of 58 million yuan, a year-on-year increase of 190.86% [2]